[December 22, 2014]

The Rosen Law Firm Announces Investigation of Roka Bioscience, Inc. - ROKA

The Rosen Law Firm announces that it is investigating potential securities claim against Roka Bioscience, Inc. ("Roka", or the "Company") (NASDAQ: ROKA) resulting from allegations that the Company may have failed to disclosed known trends and uncertainties.

Roka derives its revenues from selling Atlas diagnostic instruments and proprietary Atlas Detection Assays for use in the instruments. Roka's revenues depends crucially on the number of Atlas diagnostic instruments it has been able to install. Roka is at an early stage of commercialization.

Roka conducted its Initial Public Offering ("IPO") on July 17, 2014, boasting that it had installed 36 Atlas instruments, selling its shares at $12 each. But on Noember 6, 2014, Atlas announced a surprise loss of ($0.64) per share in the third quarter of 2014. Atlas also admitted that it had not placed any Atlas instruments in that quarter. That day, Roka's stock price fell from $8.34 to $3.00, damaging investors.

The Rosen Law Firm is investigating a securities class action lawsuit on behalf of Roka investors. If you purchased Roka stock before November 7, 2014, please visit the website at http://rosenlegal.com for more information. You may also contact Jonathan Horne, Esq., or Phillip Kim, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

[ Back To TMCnet.com's Homepage ]